Caricamento...
Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
AIMS: Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. Erythrocytes may prevent rapid removal of drugs from plasma. Erythrocytes are b...
Salvato in:
| Pubblicato in: | Cardiovasc Hematol Disord Drug Targets |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Bentham Science Publishers
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360916/ https://ncbi.nlm.nih.gov/pubmed/31533604 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1871529X19666190918141859 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|